|
Cours en clôture
Shanghai S.E.
05/08/2026
|
Varia. 5j.
|
Varia. 1 janv.
|
|
23,62 CNY
|
-4,14%
|
 |
-1,62%
|
-15,64%
|
|
10/07 |
China Includes Two Mayinglong Pharmaceutical Products in Essential Medicines List
| | |
25/05 |
Mayinglong Pharmaceutical Gets Regulatory Approval for Eye Drops
| | |
27/04 |
Mayinglong Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on August 05, 2026
| | |
24/04 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
| | |
24/04 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
| | |
29/10/25 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025
| | |
28/08/25 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025
| | |
25/04/25 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025
| | |
02/04/25 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024
| | |
02/04/25 |
Mayinglong Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on August 08, 2025
| | |
10/12/24 |
Mayinglong Pharmaceutical Group's MYL Ointment Gets Regulatory Approval for Clinical Trials
| | |
25/10/24 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024
| | |
26/08/24 |
Mayinglong Pharmaceutical's H1 Profit Rises 11%, Operating Income Jumps 18%
| | |
23/08/24 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024
| | |
07/08/24 |
Mayinglong Pharmaceutical Group Gets Registration Certificate for Antibacterial Eye Drops
| | |
19/04/24 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
| | |
17/04/24 |
Mayinglong Pharmaceutical Receives Registration Approval for New Colorectal Treatment
| | |
12/04/24 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
| | |
27/10/23 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
| | |
25/08/23 |
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
| | |
28/04/23 |
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023
| | |
07/04/23 |
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2022
| | |
14/12/22 |
Hangzhou Yunbai Pharmaceutical Technology Co., Ltd. agreed to acquire 86.816% of stake in Shenzhen Daphne Pharmaceautical Co.,Ltd from from Mayinglong Pharmaceutical Group Co., LTD., Huayi Development Co., Ltd., China Bao An Co., Ltd and Guofa Jianfu Industrial Co., Ltd. for approximately CNY 260 million.
| | |
25/10/22 |
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2022
| | |
19/08/22 |
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Half Year Ended June 30, 2022
| |
Aucun résultat pour cette recherche Sélectionnez votre édition Toutes les informations financières adaptées au niveau national | 
